• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
ALDX

ALDX

Aldeyra Therapeutics, Inc.

NASDAQHealthcareBiotechnologyUS

USD1.86

+0.22 (+13.41%)

Rating:B-

Company Profile

CEO

Todd C. Brady

IPO Date

2014-05-02

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$1.64

Prev. Close

$1.64

Day Low

$1.59

Day High

$1.87

52W Low

$1.07

52W High

$6.17

Market Cap

$0.11B

Volume

1.95M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

41.4%

Avg Negative

2.2%

Avg Neutral

56.2%

News Feed

Aldeyra's (ALDX) ADX-2191 Gets Orphan Drug Tag for Rare Cancer

Zacks Investment Research·7/21/2021·↑ positive

Aldeyra Stock Trading Higher On FDA Orphan Drug Tag For Primary Vitreoretinal Lymphoma Candidate

Benzinga·7/20/2021·↑ positive

Aldeyra Therapeutics: A New Approach To Ocular Inflammatory Diseases With Impressive Clinical Data

Seeking Alpha·6/1/2021·↑ positive

Aldeyra Therapeutics to Participate in Fireside Chat at the Jefferies Virtual Healthcare Conference

Business Wire·5/27/2021·↑ positive

Aldeyra Therapeutics, Inc. (ALDX) CEO Todd Brady on Q1 2021 Results - Earnings Call Transcript

Seeking Alpha·5/6/2021·↓ negative

Aldeyra Therapeutics, Inc. Announces Pricing of $125 Million Public Offering of Common Stock

Business Wire·4/28/2021·↑ positive

Why Aldeyra Therapeutics Stock Is Sinking Today

The Motley Fool·4/28/2021·↑ positive

Aldeyra Seeks To Raise $125M Via Equity To Support Reproxalap US Application

Benzinga·4/28/2021·↑ positive

Why Aldeyra Therapeutics Stock Is Soaring Today

The Motley Fool·4/27/2021·↑ positive

ALDX Stock: Over 25% Increase Pre-Market Explanation

Pulse2·4/27/2021·↑ positive